Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 13/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077927 | 1.00 | CYP3A4 (0.50) | CYP3A4CYP2D6FAAHGRIN2BHTR2A | |
| SCHEMBL1035753 | 0.91 | CYP3A4 (0.51) | CYP3A4CYP2D6FAAHHTR2AHTR2C | |
| SCHEMBL1035752 | 0.91 | CYP3A4 (0.51) | CYP3A4CYP2D6FAAHHTR2AHTR2C | |
| SCHEMBL1076694 | 0.91 | CYP3A4 (0.49) | CYP3A4CYP2D6FAAHGRIN2BTSHR | |
| SCHEMBL1076692 | 0.91 | CYP3A4 (0.49) | CYP3A4CYP2D6FAAHGRIN2BTSHR | |
| SCHEMBL1075908 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2D6FAAHGRIN2BHTR2A | |
| SCHEMBL1075906 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2D6FAAHGRIN2BHTR2A | |
| SCHEMBL1035939 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2D6FAAHGRIN2BHTR2A | |
| SCHEMBL1035938 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2D6FAAHGRIN2BHTR2A | |
| SCHEMBL1076160 | 0.89 | CYP3A4 (0.52) | CYP3A4CYP2D6FAAHGRIN2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144159-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC | 2011-06-16 | — | — | US | disclosed |
| EP-2276735-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127944-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144159-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, PAH | CYP3A4 329/4885CYP2D6 382/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.